Objective: The purpose of this study was to establish the relationship of plasma levels of brain natriuretic peptide (BNP) to physiologic parameters and cardiac morphologic characteristics in a population of young athletes. Our hypothesis is that physiologic and cardiac morphologic characteristics do not predict BNP levels in adolescent athletes.
INTRODUCTION
Brain, or B-type, natriuretic peptide (BNP) is a 32 amino acid peptide synthesized and secreted from the human heart in response to left ventricular (LV) wall stress. It has been shown to cause natriuresis, inhibit the renin-angiotensin-aldosterone system, reduce plasma volume, and modulate vascular tone. 1 Plasma BNP levels have been reliably demonstrated to be elevated in several cardiomyopathic states, including systolic and diastolic dysfunction, LV hypertrophy, hypertrophic cardiomyopathy (HCM), and abnormal LV filling patterns. 1, 2 BNP levels have been found to be transiently elevated in competitive athletes engaged in endurance events. 3 Although plasma levels of BNP have been studied in healthy adult athletes and found to correlate to LV mass, 4 this is not without contradictory findings. 5 It has been suggested that BNP may be useful to screen for HCM in young athletes. 6 Bedside testing of plasma BNP levels is rapid and inexpensive, and shows linear measurements of BNP between 5 and 1300 pg/mL. Normal values for plasma BNP have been established in healthy controls from neonates to adolescents 7 ; however, there are no data currently available regarding correlation of BNP and physiologic characteristics of hearts in young athletes. The purpose of this study is to measure plasma levels of BNP and to determine its correlation to physiologic parameters and cardiac morphologic characteristics in a population of young athletes.
METHODS
Thirty males between the ages of 14 and 18 years from the local state champion high school football team were asked to voluntarily participate upon scheduling a state-required preparticipation physical exam. For purposes of detecting a meaningful difference in BNP levels from published reports, a cohort of 30 subjects should yield a statistical power .0.8, the number being capped at 30 due to availability of study resources. Participants would have been excluded from consideration if they had known cardiac disease or congenital malformation, kidney disease, or history of cardiac surgery; none met exclusion criteria.
Data collection occurred during the off-season (summer). Participants refrained from hard physical activity for 24 hours before the study. Study subjects filled out a standardized questionnaire for preparticipation physical exams; had blood pressure, heart rate, height, and weight determinations; and underwent physical exam.
A single venous sample of blood was collected from each participant. Plasma BNP levels were then measured according to the manufacturer's instructions within 2 hours on the Triage BNP testing meter (Biosite, Inc, San Diego, California).
Each study participant had an electrocardiogram (ECG) performed, which was interpreted by a board-certified pediatric cardiologist. Each study participant underwent limited LV echocardiography, although the pediatric cardiologist was present to oversee the procedure and interpret the results. The pediatric cardiologist was blinded to the results of the BNP measurement.
LV mass index was calculated by dividing the LV mass by body surface area (BSA).
Left ventricular wall thickness ¼ IVSTd þ LVPWd:
Relative wall thickness ¼ IVSTd þ LVPWd=LVEDD:
Descriptive statistics were employed to define the cohort, and ECG findings were described. BNP levels were compared, with univariate linear regression analysis, with body mass index (BMI), mean arterial pressure (MAP), and echocardiographic parameters. Significance level defined as P , 0.05. All statistics were completed on SPSS version 10.0 (SPSS Inc, Chicago, Illinois).
Ethical Considerations
Institutional review board approval was obtained from Boise State University before study initiation. Written informed consent was obtained from all participants and their legal guardians. Table 1 . There were no abnormal cardiovascular findings on any physical exam.
RESULTS

Characteristics of study subjects are presented in
ECG characteristics of study subjects are presented in Table 2 . No echocardiographic abnormalities were found.
Plasma BNP measurements (mean 6 SD) were 11.9 6 10.2 pg/mL and ranged from undetectable (,5 pg/mL) to 41.7 pg/mL.
Echocardiographic characteristics of study subjects are presented in Table 3 .
There was no significant correlation between BNP values and MAP (r = 20.09, P = 0.64), BMI (r = 0.11, P = 0.57), interventricular septal thickness (r = 20.15, P = 0.44), LV wall thickness (r = 0.00, P = 0.99), relative wall thickness (r = 20.04, P = 0.84), LV mass (r = 0.05, P = 0.79), or LV mass index (r = 0.11, P = 0.55). Scatter diagram is shown in Figure 1 .
DISCUSSION
Our results document levels of plasma BNP and the ECG and echocardiographic characteristics of a healthy young male group of athletes and find no significant correlation between the plasma BNP levels measured in these athletes and BMI, MAP, or observed cardiac parameters.
Morphologic evaluation of the heart has been reliably conducted since the early 1970s with echocardiography, the noninvasive use of ultrasound-generated images of the heart to quantify cardiac dimensions and dynamic function. 8 Since that time, ranges of cardiac dimensions have been studied and described in virtually all populations, including children, 9, 10 athletes, 4, [11] [12] [13] [14] [15] [16] [17] and patients with HCM. 18, 19 Echocardiography has also allowed the morphologic characterization of athlete's heart syndrome, a constellation of physiologic adaptations to exercise that maintains or enhances cardiac function in response to stress. 20 The development of biventricular enlargement in athlete's heart syndrome presents a challenge in differentiating young athletes with HCM from those with cardiac adaptation to exercise. 21 Reference echocardiographic measurements in children and adolescents have been historically based on normalizing values to BSA. 9,10 Studies describing norms and upper limits of cardiac measurements in young athletes are given for comparison in Table 4 . Echocardiography in our study population (Table 3 ) did not reveal any pathologic cardiac lesions, and measurements obtained were mostly below the upper limits of normal in young athletes.
The ECG findings in our population of athletes were in keeping with prior descriptions of athletic subjects 20 and of normal adolescents. All the features noted by ECG have been found in populations of athletes without pathologic cardiac changes and have been attributed to physiologic adaptation to enhance cardiac function, including increased parasympathetic tone and biventricular enlargement. 20 This underscores an important point about ECG in athletes and adolescents: Benign aberrances in ECGs are common and may demonstrate an electrophysiologic adaptation to exercise that has not grossly manifested as a morphologic adaptation. In this regard, these ECG findings should be viewed as normal.
The Breathing Not Properly Study established BNP levels .100 pg/mL to be sensitive at differentiating congestive heart failure from lung disease in the emergency department 22 ; this has been further stratified to differentiate ''gray zone'' BNP levels from 100 to 500 pg/mL in the Rapid Emergency Department Heart Failure Outpatient Trial study. 23 In practice, utilizing BNP for heart failure diagnosis and monitoring must take into consideration factors such as age and sex, but there are generally no situations where BNP levels are routinely and persistently elevated .100 pg/mL without underlying cardiac pathology. 24 We were able to identify 3 studies published specifically to describe normal levels of BNP from neonates to adolescents. 7, 25, 26 Several studies have reported the value of using plasma BNP levels in children to assess status of various cardiac disorders, including ventricular septal defect, 27 heart transplant, 28 congestive heart failure versus lung disease, 29 chemotherapy, 30 Duchenne muscular dystrophy, 31 Kawasaki disease, 32 and congenital heart disease. 33, 34 These studies have reported BNP levels from 20 to 100 pg/mL as sufficiently sensitive and specific to discern a clinical difference. Although the utility of BNP measurement in HCM has yet to be fully elucidated, 35, 36 it has been suggested that increased expression of BNP may be a characteristic feature of HCM. 2 BNP values from our study population of 11.9 6 10.2 pg/mL are comparable to prior studies of BNP levels in normal adolescents 7, 26 (Table 5 ). To our knowledge, this is the first study on BNP levels in a population of adolescent athletes.
It should be acknowledged that this study was limited by a small sample size and the fact that no subjects showed abnormal cardiac structural changes. Results should be interpreted in this light and used as a basis for further studies on the subject.
CONCLUSIONS
Our findings demonstrate that adolescent athletes have similar levels of BNP when compared with normal healthy children and imply that there is no correlation between LV morphology and BNP levels in a young healthy athletic population. Future research should evaluate BNP levels in other athletic groups and in athletes with echocardiographic changes of increased LV mass, to better define the role of BNP levels in detecting cardiac pathology. 
